Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Expands By 34.6%

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 585,089 shares, an increase of 34.6% from the January 15th total of 434,784 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily volume of 295,407 shares, the days-to-cover ratio is presently 2.0 days. Based on an average daily volume of 295,407 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.6% of the shares of the stock are short sold.

Harvard Bioscience Price Performance

NASDAQ:HBIO traded up $0.04 during trading hours on Tuesday, reaching $0.60. 319,909 shares of the company were exchanged, compared to its average volume of 464,826. The firm has a market cap of $26.68 million, a price-to-earnings ratio of -0.49 and a beta of 1.55. The stock has a 50 day simple moving average of $0.63 and a 200 day simple moving average of $0.56. Harvard Bioscience has a 52-week low of $0.28 and a 52-week high of $1.38.

Institutional Investors Weigh In On Harvard Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legato Capital Management LLC lifted its stake in shares of Harvard Bioscience by 210.4% in the 4th quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 29,462 shares in the last quarter. Jane Street Group LLC lifted its position in Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 58,785 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Harvard Bioscience by 291.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 37,057 shares during the period. Gamco Investors INC. ET AL acquired a new stake in shares of Harvard Bioscience in the fourth quarter worth $38,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Harvard Bioscience by 278.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 139,220 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 102,419 shares during the period. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HBIO has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Zacks Research raised Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Finally, Wall Street Zen raised Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Harvard Bioscience presently has an average rating of “Hold” and a consensus target price of $2.00.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.